Christopher Raymond
Stock Analyst at Piper Sandler
(2.50)
# 2,295
Out of 4,876 analysts
136
Total ratings
50.46%
Success rate
-1.65%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $126.08 | -8.79% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.41 | +2,117.84% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $55.18 | +128.34% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.51 | +164.90% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $3.70 | +116.22% | 8 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $128.11 | -7.11% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $441.30 | +20.78% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $521.00 | +94.43% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $36.52 | +283.35% | 5 | Jan 13, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $43 → $30 | $3.99 | +651.88% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $33.39 | +115.63% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $182.31 | +20.67% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.46 | +793.47% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $4.33 | +1,632.10% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $14.09 | +439.39% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.44 | +594.44% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.10 | +262.64% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.38 | +194.12% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $7.43 | +465.28% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $7.11 | +209.64% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $3.65 | +9.59% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $6.60 | +278.79% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $277.13 | +3.92% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $33.51 | +22.37% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $52.49 | -46.66% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $79.67 | -49.79% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $4.72 | +1,806.78% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.11 | +4,449.76% | 2 | Mar 13, 2020 |
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $126.08
Upside: -8.79%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.41
Upside: +2,117.84%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $55.18
Upside: +128.34%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.51
Upside: +164.90%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $3.70
Upside: +116.22%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $128.11
Upside: -7.11%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $441.30
Upside: +20.78%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $521.00
Upside: +94.43%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $36.52
Upside: +283.35%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $43 → $30
Current: $3.99
Upside: +651.88%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $33.39
Upside: +115.63%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $182.31
Upside: +20.67%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.46
Upside: +793.47%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $4.33
Upside: +1,632.10%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $14.09
Upside: +439.39%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.44
Upside: +594.44%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $9.10
Upside: +262.64%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.38
Upside: +194.12%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $7.43
Upside: +465.28%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $7.11
Upside: +209.64%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $3.65
Upside: +9.59%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $6.60
Upside: +278.79%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $277.13
Upside: +3.92%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $33.51
Upside: +22.37%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $52.49
Upside: -46.66%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $79.67
Upside: -49.79%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $4.72
Upside: +1,806.78%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.11
Upside: +4,449.76%